RhumbLine Advisers
HOWL icon

RhumbLine Advisers’s Werewolf Therapeutics HOWL Stock Holding History

RhumbLine Advisers’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,231
Closed -$30.3K – 4192
2025
Q1 		$30.3K Buy
31,231
+2,315
+8% +$3.03K ﹤0.01% 3669
2024
Q4 		$42.8K Buy
28,916
+520
+2% +$1.06K ﹤0.01% 3685
2024
Q3 		$60.2K Sell
28,396
-4,151
-13% -$9.44K ﹤0.01% 3652
2024
Q2 		$79.4K Buy
+32,547
New +$156K ﹤0.01% 3582
2022
Q2 		– Sell
-22,550
Closed -$99K – 3155
2022
Q1 		$99K Buy
22,550
+3,245
+17% +$22.7K ﹤0.01% 2886
2021
Q4 		$230K Buy
+19,305
New +$291K ﹤0.01% 2795

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RhumbLine Advisers's HOWL Position: Q2 2025 in Review

RhumbLine Advisers sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 31,231 shares — an estimated $30.3K sold.

RhumbLine Advisers first reported a position in HOWL in Q4 2021 and held it in 6 quarters. The position peaked at $230K in Q4 2021. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • RhumbLine Advisers reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 31,231 Werewolf Therapeutics shares in Q2 2025, an estimated $30.3K.
  • RhumbLine Advisers first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 6 quarters.
  • RhumbLine Advisers's Werewolf Therapeutics position peaked at $230K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.